Vigil Neuroscience (NASDAQ:VIGL) Shares Up 0.4% - Time to Buy?

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report)'s share price was up 0.4% on Tuesday . The stock traded as high as $8.03 and last traded at $8.02. Approximately 580,307 shares traded hands during trading, a decline of 15% from the average daily volume of 683,086 shares. The stock had previously closed at $7.99.

Analysts Set New Price Targets

Several analysts have weighed in on VIGL shares. Citigroup cut Vigil Neuroscience to a "market perform" rating in a research report on Thursday, May 22nd. Mizuho downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Stifel Nicolaus downgraded Vigil Neuroscience from a "buy" rating to a "hold" rating and cut their target price for the company from $11.00 to $8.00 in a research note on Wednesday, May 28th. William Blair downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $10.80.

Vigil Neuroscience Stock Down 0.1%

The company has a fifty day moving average price of $6.17 and a 200-day moving average price of $3.48. The stock has a market capitalization of $382.00 million, a P/E ratio of -3.91 and a beta of 3.34.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, research analysts expect that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Vigil Neuroscience

A number of large investors have recently modified their holdings of VIGL. Cubist Systematic Strategies LLC increased its position in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new stake in Vigil Neuroscience in the fourth quarter valued at $83,000. Barclays PLC boosted its holdings in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after acquiring an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after acquiring an additional 49,000 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.